Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Anthropometric parameters and fasting levels of the blood parameters before and after the intake of control or active FM

From: Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects

Parameters Period W0 W4 Change from W0 P value
Anthropometric parameters
 Body weight Control 70.5 (2.4) 70.3 (2.4) −0.23 (0.26) 0.093
  (kg) Active 70.7 (2.4) 70.6 (2.3) −0.04 (0.12)
 BMI Control 24.5 (0.5) 24.4 (0.5) −0.09 (0.09) 0.512
  (kg/m2) Active 24.5 (0.5) 24.5 (0.5) −0.01 (0.04)
 Waist Control 87.4 (1.5) 85.6 (1.3) −1.78 (0.53) 0.461
  (cm) Active 85.4 (1.5) 84.7 (1.4) −0.75 (0.35)
Blood parameters
 TAG Control 246.5 (18.9) 272.4 (26.9) 25.9 (24.9) 0.528
   (mg/dl) Active 268.3 (31.5) 273.4 (33.5) 5.2 (14.4)
 NEFA Control 0.382 (0.033) 0.472 (0.034) 0.090 (0.037) 0.0003
   (mEq/l) Active 0.399 (0.031) 0.344 (0.026) −0.056 (0.026)
 Apo B-48 Control 9.38 (1.44) 9.98 (1.31) 0.59 (0.76) 0.173
   (μg/ml) Active 10.24 (2.06) 9.25 (1.46) −0.98 (0.89)
 Total cholesterol Control 215.7 (9.1) 220.5 (8.6) 4.8 (4.3) 0.797
   (mg/dl) Active 214.1 (7.0) 217.2 (7.8) 3.1 (4.4)
 LDL cholesterol Control 128.7 (8.3) 132.5 (7.1) 3.8 (4.0) 0.347
   (mg/dl) Active 127.0 (7.0) 125.0 (7.3) −2.0 (3.4)
 HDL cholesterol Control 43.5 (2.0) 43.4 (2.1) −0.2 (0.8) 0.504
   (mg/dl) Active 43.6 (2.4) 42.4 (2.2) −1.2 (1.2)
 Glucose Control 94.5 (2.0) 94.1 (2.0) −0.4 (1.0) 0.883
   (mg/dl) Active 93.4 (2.6) 93.4 (2.0) 0.0 (1.9)
 Insulin Control 9.01 (0.66) 8.60 (0.85) −0.41 (0.46) 0.998
   (μU/ml) Active 10.63 (2.39) 10.22 (0.95) −0.41 (2.45)
 Amylase Control 81.5 (8.3) 94.3 (21.1) 12.8 (14.5) 0.217
   (U/l) Active 103.5 (21.4) 91.5 (15.3) −12.0 (8.6)
 HbA1c Control 5.04 (0.04) 5.01 (0.05) −0.03 (0.03) 0.002
   (%) Active 5.05 (0.05) 5.13 (0.05) 0.08 (0.01)
 Total protein Control 7.05 (0.07) 7.14 (0.06) 0.09 (0.05) 0.192
   (g/dl) Active 6.99 (0.07) 7.00 (0.07) 0.01 (0.04)
 ALP Control 215.9 (13.0) 219.3 (13.5) 3.4 (4.6) 0.421
   (U/l) Active 209.3 (12.3) 227.5 (20.8) 18.2 (16.2)
 AST Control 20.8 (1.2) 20.7 (1.2) −0.1 (0.8) 0.974
   (U/l) Active 21.0 (1.2) 21.0 (1.1) 0.0 (0.9)
 ALT Control 24.8 (1.8) 24.2 (2.3) −0.6 (1.7) 0.674
   (U/l) Active 23.2 (2.1) 23.9 (1.9) 0.7 (1.7)
 LDH Control 159.9 (3.4) 159.3 (3.0) −0.6 (1.8) 0.055
   (U/l) Active 154.4 (2.9) 161.2 (4.2) 6.8 (2.6)
 γ-GTP Control 49.2 (7.5) 52.8 (7.0) 3.7 (3.0) 0.484
   (U/l) Active 48.3 (7.1) 61.6 (17.3) 13.4 (12.3)
 Total bilirubin Control 0.82 (0.09) 0.81 (0.06) −0.01 (0.06) 0.088
   (mg/dl) Active 0.88 (0.06) 0.71 (0.06) −0.18 (0.04)  
  1. Abbreviations: TAG triacylglycerol, NEFA non-esterified fatty acid, Apo apolipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein, HbA1c hemoglobin A1c, ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactase dehydrogenase, γ-GTP gamma-glutamyl transpeptidase. The data are expressed as mean (SE) at each time point before (week 0, W0) and after (week 4, W4) intake of control or active FM (n = 20). A paired t test was performed to compare the changes in the response to the control and active FM.